Pittsburgh, July 24, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced the issuance by the Japan Patent Office and China’s National Intellectual Property Administration of composition of matter patents for Elayta™, Cognition’s lead clinical stage compound in development for individuals with Alzheimer’s disease.
Elayta is a highly brain penetrant small-molecule drug that was designed by Cognition’s scientific team, led by co-founder and chief science officer, Susan Catalano, Ph.D., to stop the characteristic synapse damage and loss associated with neurodegenerative diseases such as Alzheimer’s. Elayta is currently being tested for the treatment of mild-to-moderate Alzheimer’s disease in a comprehensive Phase 2 clinical program.
Kenneth I. Moch, Cognition’s president and CEO stated, “Alzheimer’s disease is a devastating condition that effects an estimated 35 million people worldwide and drains over $600 billion in healthcare costs. With the issuance of these patents, Cognition patent portfolio now extends globally, including the three major pharmaceutical markets - US, Europe and Japan - as well as other key countries. Elayta’s worldwide patent coverages reflects the enormity of the societal tsunami that is Alzheimer's disease, positioning us to reach all major geographies in the future.”
About Cognition Therapeutics, Inc.
Cognition Therapeutics is a clinical stage biopharmaceutical company developing small-molecule therapeutics that address the toxic oligomeric proteins that cause synapse degeneration and trigger neurodegenerative conditions such as Alzheimer’s disease.
Cognition’s lead candidate, Elayta™, is a novel first-in-class, orally available small molecule that has shown the potential in initial clinical studies to normalize protein trafficking and lipid metabolism pathways that are disrupted in Alzheimer’s disease and to allow the protection and restoration of synapses. Elayta is currently being tested for the treatment of mild-to-moderate Alzheimer’s disease in three ongoing Phase 2 clinical studies: SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition); SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients); and SHINE (Synaptic Health and Improvement of Neurological Function with Elayta). These studies are supported by grants (award numbers RF1AG057780, RF1AG057553 and R01AG058660) from the National Institute on Aging of the NIH. Elayta has been granted Fast Track designation by the U.S. FDA.
Elayta and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at www.cogrx.com.
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.
Cognition Therapeutics, Inc.